Thrombotech Technologies Ltd. has raised $800,000 from its current shareholders, Hadasit Bio Holdings Ltd. (TASE:HDST), Ofer Hi Tech Ltd., and Clal Biotechnology Industries Ltd. (TASE: CBI). The investors have an option to invest an additional $2.4 million later on. RELATED ARTICLES Patience pays in biotech Thrombotech will use the proceeds to finance the Phase I clinical trial of its stroke treatment drug. Hadasit Bio owns 35% of Thrombotech, Ofer Holdings Group venture capital arm Ofer Hi Tech owns 25%, and Nochi Dankner-controlled IDB Holding Corp. Ltd. (TASE:IDBH) Clal Biotech owns 40%. Dr. Marian Gorecki is Thrombotech's chairman and Dr. Itschak Lamensdorf is the CEO. Published by Globes [online], Israel business news - www.globes-online.com - on November 8, 2009 © Copyright of Globes Publisher Itonut (1983) Ltd. 2009